Latest Biotech News

Bristol Myers Squibb reported Phase 2 QUINTESSENTIAL results for its BCMA-directed CAR T arlocabtagene autoleucel, signaling improved overall and complete response rates in relapsed or refractory...

The FDA granted accelerated approval to AstraZeneca’s next-generation oral SERD camizestrant (Etcamah) for a defined group of HR+/HER2– advanced breast cancer patients with ESR1 mutations, despite...

Moonwalk Biosciences raised $70 million in Series B funding to advance its adipose-targeted siRNA obesity program MW101 into IND-enabling work and first-in-human trials planned for late 2027. The...

Solstice Oncology secured $225 million in a Series A to develop a next-generation immunotherapy targeting CTLA-4, advancing a medicine sourced from Harbour BioMed. The startup said its approach...

Bristol Myers Squibb reported that its pivotal multiple myeloma CAR T trial using a GPRC5D-directed construct hit its primary endpoint, extending the company’s push to challenge Johnson & Johnson...

Roivant Sciences reported that mosliciguat achieved its primary and key secondary endpoints in a 16-week Phase 2 study in pulmonary hypertension, supporting a potential expansion of treatment...

GSK expanded its antibody-drug conjugate efforts by taking ex-China rights to Hutchmed’s preclinical KRAS/EGFR antibody conjugate HMPL-A830 in a deal valued up to $1.295 billion plus...

NodThera, a decade-old biotech focused on the NLRP3 inflammasome pathway, announced plans for pivotal Phase 3 trial development beginning in 2027 along with a corporate rebrand. The company said...

Ciliatech SAS received a U.S. FDA investigational device exemption (IDE) to begin a feasibility study of its Intercil Uveal Spacer implant for glaucoma. The IDE allows the company to test the...

Novartis took another major hit to its late-stage pipeline as delpacibart etedesiran failed to meet the primary endpoint in the pivotal Phase 3 HARBOR trial in myotonic dystrophy type 1 (DM1). In...

The FDA granted accelerated approval to AstraZeneca’s oral SERD camizestrant, branded Etcamah, for patients with HR+/HER2– advanced breast cancer with ESR1 mutations detected during aromatase...

GSK agreed to acquire ex-China rights to Hutchmed’s HMPL-A830, a KRAS inhibitor antibody conjugate, in a deal valued at up to $1.295 billion plus royalties. The agreement reflects GSK’s push into...

Fortrea agreed to buy Worldwide Clinical Trials’ early-phase services business in a $45 million deal, adding three Texas facilities and a 200-bed clinical pharmacology unit to its network. The...

Ciliatech SAS received a U.S. FDA investigational device exemption (IDE) to run a feasibility study of Intercil Uveal Spacer, its implant aimed at treating glaucoma. The step allows the company to...

Moonwalk Biosciences raised $70 million in a Series B round to advance its adipose-targeted RNAi candidate MW101 toward first-in-human clinical trials. The company plans to use the funding to...

Inhibrx announced first win data for its OX40 agonist immunotherapy in head and neck cancer, reporting responses that were most striking in a subset of patients with HPV-positive tumors. The...

BrainChild Bio secured $116 million in Series A financing to support its pivotal pediatric CAR-T program for diffuse intrinsic pontine glioma (DIPG). The lead candidate BCB-276 targets B7-H3 and...

Researchers reported that microwave ablation can trigger more than direct tumor cell destruction, with a new preclinical study suggesting benefit from pairing the treatment with anti–LAG-3 immune...

ARPA-H selected RNAV8 Bio for PROPEL, a one-year pilot program aimed at advancing programmable RNA medicines through a funding award of up to $4.4 million. The initiative will be led by the...

Novartis reported two major late-stage setbacks in rapid succession, including the Phase III failure of delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 and the Phase III failure...